Xizang Haisco Pharmaceutical Group Co Ltd Market Cap ($9.15 Billion)
Market Cap & Net Worth: Xizang Haisco Pharmaceutical Group Co Ltd (002653)
Xizang Haisco Pharmaceutical Group Co Ltd market cap. Xizang Haisco Pharmaceutical Group Co Ltd (SHE:002653) has a market capitalization of $9.15 Billion (CN¥62.54 Billion) as of October 31, 2026. Listed on the SHE stock exchange, this China-based company holds position #2307 globally and #220 in its home market, demonstrating a -7.07% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Xizang Haisco Pharmaceutical Group Co Ltd's stock price CN¥54.82 by its total outstanding shares 1140892480 (1.14 Billion).
Xizang Haisco Pharmaceutical Group Co Ltd Market Cap History (2015–2026)
Xizang Haisco Pharmaceutical Group Co Ltd market cap history from 2015 to 2026. Data shows growth from $3.21 Billion to $9.15 Billion (9.62% CAGR). Check Xizang Haisco Pharmaceutical Group Co Lt stock quote for real-time trading data and today's change.
Xizang Haisco Pharmaceutical Group Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Xizang Haisco Pharmaceutical Group Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see Xizang Haisco Pharmaceutical Group Co Lt cash conversion from operations for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
1.95x
Xizang Haisco Pharmaceutical Group Co Ltd's market cap is 1.95 times its annual revenue
Latest Price to Earnings (P/E) Ratio
33.01x
Xizang Haisco Pharmaceutical Group Co Ltd's market cap is 33.01 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.33 Billion | $1.44 Billion | $442.78 Million | 1.62x | 5.26x |
| 2017 | $1.75 Billion | $1.86 Billion | $237.55 Million | 0.94x | 7.38x |
| 2018 | $1.88 Billion | $3.43 Billion | $333.23 Million | 0.55x | 5.63x |
| 2019 | $3.27 Billion | $3.94 Billion | $493.89 Million | 0.83x | 6.61x |
| 2020 | $2.82 Billion | $3.33 Billion | $636.62 Million | 0.85x | 4.43x |
| 2021 | $3.33 Billion | $2.77 Billion | $345.06 Million | 1.20x | 9.65x |
| 2022 | $3.67 Billion | $3.02 Billion | $277.07 Million | 1.22x | 13.26x |
| 2023 | $3.82 Billion | $3.36 Billion | $295.11 Million | 1.14x | 12.95x |
| 2024 | $5.55 Billion | $3.72 Billion | $395.46 Million | 1.49x | 14.04x |
| 2025 | $8.57 Billion | $4.39 Billion | $259.58 Million | 1.95x | 33.01x |
Competitor Companies of 002653 by Market Capitalization
Companies near Xizang Haisco Pharmaceutical Group Co Ltd in the global market cap rankings as of October 31, 2026. See 002653 net asset quality index to understand what proportion of total assets are financed by equity.
Key companies related to Xizang Haisco Pharmaceutical Group Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Xizang Haisco Pharmaceutical Group Co Ltd (2015–2026)
Market capitalization of Xizang Haisco Pharmaceutical Group Co Ltd from 2015 to today. Between 2015 and today, Xizang Haisco Pharmaceutical Group Co Ltd's market cap moved from $3.21 Billion to $ 9.15 Billion, with a yearly change of 9.62%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥9.15 Billion | +6.82% |
| 2025 | CN¥8.57 Billion | +54.35% |
| 2024 | CN¥5.55 Billion | +45.20% |
| 2023 | CN¥3.82 Billion | +4.05% |
| 2022 | CN¥3.67 Billion | +10.34% |
| 2021 | CN¥3.33 Billion | +18.08% |
| 2020 | CN¥2.82 Billion | -13.64% |
| 2019 | CN¥3.27 Billion | +73.95% |
| 2018 | CN¥1.88 Billion | +7.07% |
| 2017 | CN¥1.75 Billion | -24.65% |
| 2016 | CN¥2.33 Billion | -27.47% |
| 2015 | CN¥3.21 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Xizang Haisco Pharmaceutical Group Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.15 Billion USD |
| MoneyControl | $9.15 Billion USD |
| MarketWatch | $9.15 Billion USD |
| marketcap.company | $9.15 Billion USD |
| Reuters | $9.15 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Xizang Haisco Pharmaceutical Group Co Ltd
Haisco Pharmaceutical Group Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in China. It offers pharmaceutical products in the areas of anesthesia and analgesic, endocrine system, enteral parenteral nutrition, cardiovascular, psychiatric, tumor-related, digestive liver, and other diseases. Haisco Pharmaceutical Group Co., Ltd. has licensing and research c… Read more